Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Glioblastoma therapy: Past, present and future
E Obrador, P Moreno-Murciano… - International journal of …, 2024 - mdpi.com
Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …
Although great efforts have been made by clinicians and researchers, no significant …
[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …
representing a highly heterogeneous group of neoplasms that are among the most …
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
X Li, C Wu, N Chen, H Gu, A Yen, L Cao, E Wang… - …, 2016 - pmc.ncbi.nlm.nih.gov
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors
and currently effective treatment options are still lacking. GBM is frequently accompanied …
and currently effective treatment options are still lacking. GBM is frequently accompanied …
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
Glioblastoma multiforme (GBM) is the most common form of brain cancer and one of the
most aggressive cancers found in humans. Most of the signs and symptoms of GBM can be …
most aggressive cancers found in humans. Most of the signs and symptoms of GBM can be …
Updated insights on EGFR signaling pathways in glioma
A Oprita, SC Baloi, GA Staicu, O Alexandru… - International journal of …, 2021 - mdpi.com
Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …
is better understood. For the newly diagnosed, the current standard of care is represented by …
A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials
E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
EGFR as a target for glioblastoma treatment: an unfulfilled promise
M Westphal, CL Maire, K Lamszus - CNS drugs, 2017 - Springer
The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across
a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase …
a broad variety of tumor types. As it is a tyrosine kinase, small molecule tyrosine kinase …
Glioblastoma multiforme: State of the art and future therapeutics
TA Wilson, MA Karajannis… - Surgical neurology …, 2014 - pmc.ncbi.nlm.nih.gov
Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …
A biobank of patient-derived pediatric brain tumor models
S Brabetz, SES Leary, SN Gröbner, MW Nakamoto… - Nature medicine, 2018 - nature.com
Brain tumors are the leading cause of cancer-related death in children. Genomic studies
have provided insights into molecular subgroups and oncogenic drivers of pediatric brain …
have provided insights into molecular subgroups and oncogenic drivers of pediatric brain …
Revolutionizing glioblastoma treatment: a comprehensive overview of modern therapeutic approaches
K Sadowski, A Jażdżewska, J Kozłowski… - International Journal of …, 2024 - mdpi.com
Simple Summary Glioblastoma is one of the most dangerous tumors of the central nervous
system, and still cannot be fully overcome. We still mainly rely on standard treatments …
system, and still cannot be fully overcome. We still mainly rely on standard treatments …